Analysis of Plasma Tumor DNA in Lung Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The presence of genetic alterations in the tyrosine kinase domain of the oncogene (eg. EGFR and ALK) is associated with the clinical response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancers. Therefore, the detection of altered genetic alterations is useful for predicting the treatment response for TKIs in non-small cell lung cancer patients. However, good quality tumor tissues are available only in \<50% of patients with inoperable lung cancer for mutation analysis. In this study, the investigators will detect and quantify the genetic alterations in plasma. the investigators will investigate if the serial measurement of cancer-derived genetic alterations in plasma can provide a means for monitoring disease progression, as well as treatment response. In addition the investigators will analysis the resistant mechanism of TKIs and chemotherapy with plasma tumor DNA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection Cell Free DNA in Lung Cancer Patients

NCT02738593

Non-small Cell Lung Cancer

UNKNOWN

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

NCT05701787

NSCLC NSCLC Stage IV NSCLC, Recurrent

RECRUITING

DNA Analysis of Blood and Tissue from Patients with Lung Cancer

NCT00471978

Lung Cancer

RECRUITING

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

NCT03244904

SCLC

UNKNOWN

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

NCT06167460

Non Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IIIC Non-Small Cell Lung Cancer +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer
* Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)
* Patients must have given written informed consent